MOSCOW (MRC) -- Essen-based Evonik Industries, a leading specialty chemicals manufacturer, and Duisburger Hafen AG (duisport) are preparing to establish a jointly controlled company for the future development of Evonik's Lulsdorf location, as per the company's press release.
The 50:50 joint venture will continue to develop the premises that are available at the Lulsdorf site, and further optimize the existing on-site logistics. It is expected to be created still in 2015.
"The joint venture is designed to provide incentives for other companies to set up operations at Evonik's Lulsdorf site. This would create new workplaces and make a sustained contribution to the development of the North Rhine-Westphalia growth region," explains Wessel.
The new joint venture between Evonik and duisport in Lulsdorf will go hand in hand with the strategic collaboration that the two partners established last year. duisport has considerable logistics know-how in land development as well as port and rail handling. Through the joint venture, this expertise will be combined with Evonik's existing logistics competencies at the Lulsdorf site.
Evonik has approximately 500 employees at the Lulsdorf site, where it operates facilities to produce inorganic and organic chemicals, such as alkoxides used in the production of bio-diesel. Approximately 50 hectares of the area available at the Lulsdorf site will now be marketed to attract production and logistics companies to this location.
As MRC reported before, Evonik Industries is making an investment in the double-digit-million euro range in a new research center at the Rheinfelden site. Starting at the beginning of 2016, research into silanes will be carried out in modern laboratories in the four-story building. Silanes are used in the electronics industry, in the tire industry, for the production of adhesives and sealants as well as plastics, and in the construction industry.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2013 more than 33,500 employees generated sales of around EUR12.9 billion and an operating profit (adjusted EBITDA) of about EUR2.0 billion.
MRC